{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:38:19Z","timestamp":1777876699104,"version":"3.51.4"},"reference-count":68,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The recent development of new antileukemic therapies (anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhbitors, phosphoinositide 3-kinase inhibitors, and B-cell lymyphoma-2 antagonists) improved the progression-free survival (PFS) compared with selected standard regimens in clinical trials for patients with relapsed\/refractory chronic lymphocytic leukemia (CLL). Unfortunately, the relative efficacy of all possible therapeutic options remains unknown because there is no direct evidence for all possible comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aimed to compare the efficacy and safety of novel agents, chemotherapy, and immunotherapy using a Bayesian network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic literature review with Bayesian NMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An extensive systematic literature review of randomized clinical trials for relapsed\/refractory CLL was performed. We searched for articles indexed in medical databases (MEDLINE, Embase, The Cochrane Library) and gray literature that could be further implemented into the Bayesian NMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The systematic search identified 15 randomized trials that formed networks comparing PFS, overall survival (OS), overall response rates, and serious adverse events. Our study showed that all regimens containing novel agents significantly prolonged PFS compared with standard chemoimmunotherapy and immunotherapy. Among targeted drugs, venetoclax (VEN)\u2009+\u2009rituximab (RTX) had comparable efficacy in terms of PFS to zanubrutinib (ZAN) [hazard ratio (95% credible interval), 1.10 (0.59\u20132.08)], acalabrutinib (ACA) [0.78 (0.47\u20131.30)], ibrutinib (IBR) monotherapy [0.72 (0.41\u20131.27)], and other IBR-based regimens. ZAN was superior to IBR monotherapy [0.65 (0.49\u20130.86)] but not to ACA [0.71 (0.49\u20131.02)]. There were no significant differences in OS in any of the above comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>All novel therapies have better efficacy than chemoimmunotherapy and immunotherapy regimens. Among novel agents, the relative efficacy of VEN\u2009+\u2009RTX was similar to all BTKi, while ZAN was superior to IBR and comparable to ACA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>PROSPERO CRD42022304330.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359241263710","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T03:11:24Z","timestamp":1722395484000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Network meta-analysis of novel targeted therapies for relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-5349","authenticated-orcid":false,"given":"Magdalena","family":"Monica","sequence":"first","affiliation":[{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, \u0141azarza 16, Krak\u00f3w 31-530, Poland"},{"name":"Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Reczek","sequence":"additional","affiliation":[{"name":"HTA Consulting, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"bibr1-17588359241263710","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"bibr2-17588359241263710","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: leukemia \u2013 chronic lymphocytic leukemia (CLL), https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html (accessed December 16, 2022)."},{"key":"bibr3-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"bibr4-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01156-x"},{"key":"bibr5-17588359241263710","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results Program. Chronic lymphocytic leukemia (CLL) recent trends in SEER relative survival rates, 2000\u20132018, https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=93&data_type=4&graph_type=2&compareBy=sex&chk_sex_1=1&relative_survival_interval=5&race=1&age_range=1&hdn_stage=101&advopt_precision=2&advopt_show_ci=on&hdn_view=0&advopt_display=2#graphArea (accessed December 16, 2022)."},{"key":"bibr6-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"bibr7-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"bibr8-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"bibr9-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145926"},{"key":"bibr10-17588359241263710","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30433-6","volume":"8","author":"Sharman JP","year":"2021","journal-title":"Lancet Haematol"},{"key":"bibr11-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1232-8"},{"key":"bibr12-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"bibr13-17588359241263710","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0844"},{"key":"bibr14-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"bibr15-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"bibr16-17588359241263710","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060408"},{"key":"bibr17-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007294"},{"key":"bibr18-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.03.010"},{"key":"bibr19-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.322"},{"key":"bibr20-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054"},{"key":"bibr21-17588359241263710","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"key":"bibr22-17588359241263710","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"bibr23-17588359241263710","unstructured":"van Valkenhoef G, Kuiper J. Package \u2018gemtc\u2019, https:\/\/cran.r-project.org\/web\/packages\/gemtc\/gemtc.pdf (accessed: October 20, 2023)."},{"key":"bibr24-17588359241263710","volume":"366","author":"Sterne JAC","year":"2019","journal-title":"BMJ"},{"key":"bibr25-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082"},{"key":"bibr26-17588359241263710","volume-title":"Paper presented at the International Workshop on CLL","author":"Hillmen P"},{"key":"bibr27-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"bibr28-17588359241263710","unstructured":"European Medicines Agency. Assessment report. Brukinsa (EMA\/CHMP\/896488\/2022), https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/brukinsa-h-c-004978-ii-0003-epar-assessment-report-variation_en.pdf. (2022, accessed October 10, 2023)."},{"key":"bibr29-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146570"},{"key":"bibr30-17588359241263710","unstructured":"Center for Drug Evaluation and Research. Application package for: 210259Orig1s006 210259Orig1s007. Trade name: Calquence capsules, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/210259Orig1s006,%20s007.pdf"},{"key":"bibr31-17588359241263710","unstructured":"Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Modul 4 C: Calquence\n                      \u00ae\n                      zur Behandlung von CLL-Patienten, die mindestens eine Vorbehandlung erhalten haben, https:\/\/www.g-ba.de\/downloads\/92-975-4318\/2020-12-01_Modul4C_Acalabrutinib.pdf (2020, accessed October 10, 2023)."},{"key":"bibr32-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"bibr33-17588359241263710","volume-title":"Paper presented at the 2022 ASCO Annual Meeting","author":"Jurczak W"},{"key":"bibr34-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"bibr35-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"bibr36-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"bibr37-17588359241263710","unstructured":"European Medicines Agency. Assessment report. Copiktra (EMA\/CHMP\/236249\/2021), https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/copiktra-epar-public-assessment-report_en.pdf (2021, accessed October 10, 2023)."},{"key":"bibr38-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1795159"},{"key":"bibr39-17588359241263710","unstructured":"European Medicines Agency. Assessment report. Imbruvica (EMA\/CHMP\/623036\/2016), https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imbruvica-h-c-3791-ii-0017-epar-assessment-report-variation_en.pdf (2016, accessed October 10, 2023)."},{"key":"bibr40-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"bibr41-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1337"},{"key":"bibr42-17588359241263710","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170480"},{"key":"bibr43-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136109"},{"key":"bibr44-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00948"},{"key":"bibr45-17588359241263710","unstructured":"European Medicines Agency. Assessment report. Venclyxto (EMA\/CHMP\/717199\/2018), https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/venclyxto-h-c-4106-ii-0008-epar-assessment-report-variation_en-0.pdf (2018, accessed October 10, 2023)."},{"key":"bibr46-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"bibr47-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015014"},{"key":"bibr48-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16429"},{"key":"bibr49-17588359241263710","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1122783"},{"key":"bibr50-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"bibr51-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238"},{"key":"bibr52-17588359241263710","unstructured":"European Medicines Agency. Assessment report. Imbruvica (EMA\/CHMP\/645137\/2014), https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/imbruvica-epar-public-assessment-report_en.pdf (2014, accessed October 10, 2023)."},{"key":"bibr53-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.175"},{"key":"bibr54-17588359241263710","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2014.107706","volume":"100","author":"Ghia P","year":"2015","journal-title":"Haematologica"},{"key":"bibr55-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"bibr56-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"bibr57-17588359241263710","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30019-4","volume":"4","author":"Jones JA","year":"2017","journal-title":"Lancet Haematol"},{"key":"bibr58-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"bibr59-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000692"},{"key":"bibr60-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1233536"},{"key":"bibr61-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1732960"},{"key":"bibr62-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13061"},{"key":"bibr63-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"bibr64-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-748210"},{"key":"bibr65-17588359241263710","unstructured":"NCCN. Chronic lymphocytic leukemia\/small lymphocytic lymphoma, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf (2023, accessed 16 February 2022)."},{"key":"bibr66-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1691193"},{"key":"bibr67-17588359241263710","volume":"40","author":"Chanan-Khan A","year":"2022","journal-title":"J Clin Oncol"},{"key":"bibr68-17588359241263710","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.011"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359241263710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359241263710","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359241263710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:30:14Z","timestamp":1777588214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359241263710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":68,"alternative-id":["10.1177\/17588359241263710"],"URL":"https:\/\/doi.org\/10.1177\/17588359241263710","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17588359241263710"}}